Peptides DB
Research-centric peptide and protocol reference hub
Study 21 of 22MK-677 (Ibutamoren) literatureEClinicalMedicine · Observational2026

Predominantly genetic, intrauterine, and lifestyle aetiologies of type 2 diabetes are associated with distinct clinical presentations and risk of complications: a Danish cross-sectional and follow-up study.

Individuals with type 2 diabetes due to intrauterine or lifestyle factors may face higher risks of complications compared to those with a genetic basis for their condition.

Read at EClinicalMedicineAdd to compare

Where it sits

this study against the rest of the mk-677 (ibutamoren) corpus
1
Preclinical
17
Observational · this one
0
Open-label
3
Randomised
1
Reviews

Summary and findings

This study investigated the clinical presentations and complications of type 2 diabetes (T2D) based on predominant aetiologies: genetic, intrauterine, and lifestyle. A total of 7867 individuals with newly diagnosed T2D were included, with various metrics assessed at diagnosis and over a 10-year follow-up. The findings indicated distinct differences in insulin sensitivity, triglyceride levels, and risks of major adverse cardiovascular and microvascular events based on the aetiology classification.

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →
The 10-year risk of major adverse cardiovascular events was 14.8% for intrauterine aetiology.2026

Abstract

The authors’ words, as EClinicalMedicine supplied them

<h4>Background</h4>We investigated whether individuals who likely developed type 2 diabetes (T2D) through predominantly genetic, adverse intrauterine, or lifestyle aetiologies have different clinical presentations and complications.<h4>Methods</h4>In this Danish nationwide combined cross-sectional and registry-based follow-up study, we included 7867 individuals with newly diagnosed T2D from the DD2 cohort, enrolled during 2010-2023 through general practices and hospital outpatient clinics across Denmark. Participants were required to have available genotyping and birthweight data; those with GAD antibody levels >30 were excluded. Individuals were grouped by presumed predominant aetiologies: genetic (highest-quartile T2D genetic risk score (GRS), birthweight above lowest quartile; n = 1435); intrauterine (lowest-quartile birthweight, GRS below highest quartile; n = 1195); and lifestyle (birthweight above lowest quartile, GRS below highest quartile; n = 4380). Baseline characteristics at diagnosis were examined using linear and log-binomial or robust Poisson regression. The main follow-up outcomes were standardised 10-year risks of major adverse cardiovascular events and microvascular complications after DD2 enrolment, estimated using the Aalen-Johansen method.<h4>Findings</h4>Compared with the genetic group (18%), intrauterine (15%) and lifestyle (56%) aetiologies both showed -6.9% lower Homeostatic Model Assessment-2 (HOMA2) insulin sensitivity, higher triglycerides (+6.6% and +5.3%), higher HOMA2 beta-cell function (+8.9% and +9.6%), and higher high-sensitivity C-reactive protein (+14.8% and +24.1%). Age at T2D diagnosis was 1.2 years lower (intrauterine) and 2.3 year higher (lifestyle). The 10-year risk of major adverse cardiovascular events was 14.8% (intrauterine), 13.2% (lifestyle), and 11.5% (genetic), corresponding to absolute risk differences (RDs) of +3.3% (95% confidence interval [CI] 0.6, 6.0) for intrauterine, and +1.7% (95% CI -0.3, 3.6) for lifestyle, <i>vs</i>. genetic aetiology. The 10-year risk of microvascular complications was 25.9% (intrauterine), 25.4% (lifestyle), and 21.8% (genetic), yielding RDs of +4.1% (95% CI 0.7, 7.5) for intrauterine and +3.5% (95% CI 1.0, 6.1) for lifestyle aetiology.<h4>Interpretation</h4>Individuals who developed T2D with predominant intrauterine or lifestyle rather than genetic aetiology exhibited distinct characteristics including higher long-term complication risks. Future studies should validate this framework in more diverse populations and assess whether these proxy-based aetiological domains can improve risk stratification and guide treatment.<h4>Funding</h4>This work was funded by Danish Agency for Science, the Danish Health and Medicines Authority, the Danish Diabetes Association, the Region of Southern Denmark, the Swedish Research Council, the Novo Nordisk Foundation, the Swedish ALF for Region Skåne, the Crafoord Foundation, and the Swedish Diabetes Association.

Elsewhere in the MK-677 (Ibutamoren) corpus

BDiffusion kurtosis imaging (gen)omics unravels mechanisms of cerebral small vessel diseasebiorxiv-preprint · 2026 · Not reported in abstract.HumanBImpact of anxiety and mood disorders on elective flow diversion for unruptured intracranial aneurysms: propensity score-matched analyses of two large databases.Journal of neurointerventional surgery · 2026 · 1.9% FD treatment rate for AMD patients vs 1.5% for controls, HR 1.23 (95% CI 1.10 to 1.37), p<0.001.HumanAEffect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.The Journal of clinical endocrinology and metabolism · 2001 · MK-677 plus alendronate increased BMD at the femoral neck by 4.2% vs 2.5% for alendronate, P < 0.05.HumanCIdentification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines.The Journal of clinical endocrinology and metabolism · 2001 · Not reported in abstract.In vitroDChemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.JAMA · 2017 · 52% of products contained 1 or more selective androgen receptor modulators.reviewDHealth impacts of takeaway management zones around schools in six different local authorities across England: a public health modelling study using PRIMEtimebiorxiv-preprint · 2024 · 964 fewer cases of type II diabetes per 100,000 population for males in Manchester (95% UI: 1565, 870).review